Form 4: iBio CFO Felipe Duran Reports Stock Option Grant

Felipe Duran, CFO of iBio, Inc., reports the acquisition of stock options.

Summary

• On February 21, 2025, Felipe Duran, the Chief Financial Officer of iBio, Inc., was granted stock options to purchase 84,700 shares of iBio's common stock.
• The exercise price of these options is $3.48 per share.
• The options vest over time, with 25% vesting on the one-year anniversary of the grant date and the remaining 75% vesting in equal quarterly installments over the subsequent three years, contingent upon continued employment with iBio, Inc.
• The options expire on February 20, 2035.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. It indicates that the CFO is incentivized to perform well, which is a slight positive.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to work towards increasing the company's value.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with their own.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates

Keywords

iBio, Felipe Duran, stock options, Form 4, CFO, beneficial ownership, securities, IBIO